Molecular mechanisms of resistance to tumour anti-angiogenic strategies
about
Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environmentTargeting the hypoxic fraction of tumours using hypoxia-activated prodrugsEvolutionary foundations for cancer biologyInvestigational agents in development for the treatment of ovarian cancerPrimary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapyEndothelial cell-initiated extravasation of cancer cells visualized in zebrafish.HEXIM1 down-regulates hypoxia-inducible factor-1α protein stability.Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a reviewThe isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth.A novel taspine analog, HMQ1611, inhibits growth of non-small cell lung cancer by inhibiting angiogenesis.Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis.The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.VEGF and pleiotrophin modulate the immune profile of breast cancer.Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.In pursuit of new anti-angiogenic therapies for cancer treatmentAdvances in the approach to novel drug clinical development for breast cancer.Arf6 regulates tumour angiogenesis and growth through HGF-induced endothelial β1 integrin recycling.Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxiaRapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models.Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology.Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide.Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT.Pathological functions of the small GTPase Arf6 in cancer progression: Tumor angiogenesis and metastasis.Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.
P2860
Q24620228-7BD72D9A-7E4B-4F36-8190-416AFA7FCD8BQ26774750-758A5444-6257-47D8-A848-25C2811A2584Q28709090-92AEDD95-653D-4E05-8DBA-BC5912319D50Q33920800-6C5FCB56-5253-4E46-8C00-910591480DD4Q34067987-9D346495-B755-4848-B63D-F2CE5D1B96C3Q34777219-24E30B0C-942A-42A3-9CBD-C88979A737FDQ35602354-D264B4E9-B557-49E2-A396-72334748E6ADQ36061770-1FBD4E24-6D2E-4A4D-9136-329AE0624F2EQ36123270-5B99490A-3E7A-4884-939C-964347EC27EBQ36403368-EF281138-369E-4A51-AA3D-AA0B803A81E5Q36476333-11B3FC66-0405-4982-8FF3-243D9CF83A21Q36520728-1358ECFF-EDF0-4B00-8079-89ACEF69DF9DQ36821142-831277EC-A710-4286-A933-6C0B2DDEAAB1Q37328378-2BF390EC-99CB-4092-91A5-76B29A0724E4Q37381585-EFAAA39E-9C9D-47E1-8C63-6B1AF5DC61E8Q37653981-BB61B022-FF8C-435C-BE2C-41535ADFB11AQ37735637-74364E93-7686-4637-87C6-50FAC4CCE2FCQ37807243-B3F257BE-5A31-4947-A41C-43E02E1A6C9CQ37825180-186294D5-7680-4036-81DA-569A2305389DQ38206546-2456C9E0-3587-42D8-A32F-C296F3B98519Q38846677-F82E804C-E9E6-46EF-A323-49D5873DE36CQ38964255-EE22AAAD-8B0B-426B-BC7A-84F727ECEEC0Q39224802-F6E1AEC2-2939-4C24-BDF4-BD0DB0CEC74BQ39226446-3DDFE596-3434-40F6-BF01-6286804F90A2Q39305041-8496EE0A-8609-4E2F-A205-5779B801C818Q39360670-C4EF4C58-D108-45C9-95D8-FA1B7729719DQ39642439-3DF447EC-A6A5-4605-862E-58A07F841842Q42088910-5A73FCBE-DD56-41FC-A51B-C8879B2A7F6DQ45887249-3DF19E8D-78BB-4719-8E55-616405D215EA
P2860
Molecular mechanisms of resistance to tumour anti-angiogenic strategies
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Molecular mechanisms of resistance to tumour anti-angiogenic strategies
@ast
Molecular mechanisms of resistance to tumour anti-angiogenic strategies
@en
type
label
Molecular mechanisms of resistance to tumour anti-angiogenic strategies
@ast
Molecular mechanisms of resistance to tumour anti-angiogenic strategies
@en
prefLabel
Molecular mechanisms of resistance to tumour anti-angiogenic strategies
@ast
Molecular mechanisms of resistance to tumour anti-angiogenic strategies
@en
P2860
P356
P1433
P1476
Molecular mechanisms of resistance to tumour anti-angiogenic strategies
@en
P2093
Gilles Pagès
Renaud Grépin
P2860
P304
P356
10.1155/2010/835680
P577
2010-03-09T00:00:00Z